Boston Scientific flies to Baltimore amid ongoing MiRus investment

Boston Scientific flew from Providence, Rhode Island to Baltimore/Washington International Thurgood Marshall Airport on June 8, 2026, a 1-hour-20-minute hop in its Bombardier Challenger 650 (N650BS). The trip comes just weeks after the company finalized a $1.5 billion investment in MiRus LLC, acquiring a 33.75% equity stake and an exclusive option to buy MiRus's transcatheter aortic valve replacement business for an additional $3 billion, per an SEC filing on May 18, 2026 [sec.gov](https://www.sec.gov/Archives/edgar/data/885725/000088572526000041/bsx-20260518.htm).

Baltimore's proximity to Washington D.C. and the FDA's headquarters in Silver Spring makes it a logical destination for regulatory discussions or investor meetings related to that deal. The SIEGEL TAVR system, built on a proprietary rhenium alloy, is currently in a pivotal trial and requires ongoing dialogue with regulators, as noted in the company's May 18 press release [news.bostonscientific.com](https://news.bostonscientific.com/2026-05-18-Boston-Scientific-announces-strategic-investment-in-MiRus-LLC).

This flight continues a pattern of Washington-area visits for Boston Scientific: the aircraft frequently lands at Hanscom Field near its Marlborough headquarters but also makes regular trips to Dulles and Baltimore airports, reflecting the company's heavy engagement with federal agencies and capital-based investors.